|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||215.93 - 221.03|
|52 Week Range||177.05 - 264.97|
|Beta (5Y Monthly)||0.82|
|PE Ratio (TTM)||17.68|
|Earnings Date||Jan 28, 2021 - Feb 01, 2021|
|Forward Dividend & Yield||6.40 (2.86%)|
|Ex-Dividend Date||Nov 13, 2020|
|1y Target Est||260.08|
My name is April, and I will be your conference facilitator today for Amgen's Third Quarter 2020 Financial Results Conference Call. You'll recall that Amgen grew revenues by 11% in the first quarter of the year, with the first 10 weeks of performance largely unaffected by the pandemic.
A driver of the sales beat was the company’s success with its biosimilar versions of other biotech firms’ blockbusters.
Amgen posted third-quarter earnings and sales that beat Wall Street views and hiked it earnings outlook, and Amgen stock rose after hours after hitting four-month lows in the regular session.